Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

By The Northwire Desk — AI Analysis Feb 09, 2026 · 03:01 PREV · 0.025 PreveCeutical Medical Inc.
PREV · Price

Executive Summary

  • PreveCeutical Medical Inc. filed an international (PCT) patent application (No. PCT/US2026/014110) titled “Delivery of CNS‑active therapeutic agents.”
  • The patent covers novel methods and formulations for delivering central nervous system‑active drugs—particularly dopamine—to the brain, addressing a major unmet need in Parkinson’s disease treatment.
  • CEO Stephen Van Deventer highlighted the technology as a potential breakthrough for direct dopamine delivery, though no clinical claims are made at this stage.

Key Details

  • Patent Application: International (PCT) filing on February 5 2026; application number PCT/US2026/014110.
  • Title of Invention: “Delivery of CNS‑active therapeutic agents.”
  • Scope: Methods and formulations enabling direct delivery of CNS‑active drugs across the blood‑brain barrier, with a focus on dopamine for Parkinson’s disease.
  • Target Indication: Parkinson’s disease – aims to supply native dopamine directly to the brain, potentially bypassing levodopa therapy.
  • Potential Impact: Could provide a safe and effective treatment option for advanced Parkinson’s patients and address delivery bottlenecks for other peripherally‑restricted CNS therapeutics.
  • Company Statement: CEO Stephen Van Deventer – “Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain… our technology aims to change that.”
  • Cautionary Note: The company makes no express or implied claims regarding efficacy or regulatory approval at this time; forward‑looking statements involve substantial risk.

Notable Quotes

“Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain. Our technology aims to change that, and we believe it represents an important step toward transforming the treatment landscape for Parkinson's disease and other central nervous system disorders.” – Stephen Van Deventer, CEO & Chairman

Materiality Assessment: Material – Positive (the filing of a potentially groundbreaking patent could materially affect future valuation and strategic direction).

Read the original news release →

More from PreveCeutical Medical Inc.

May 19, 2026 · 19:36

PreveCeutical Extends Financing Deadline Amidst Liquidity Concerns

Financings May 12, 2026 · 17:02

PreveCeutical Closes Dilutive Financing Amidst Cash Burn Concerns

Financings Apr 22, 2026 · 03:02

PreveCeutical Raises Cash at Discount Amidst Dilution Concerns

Financings Feb 25, 2026 · 03:01

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

M&A / Property Dec 04, 2025 · 07:02

PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology

M&A / Property Dec 01, 2025 · 17:15

SEDAR Interim Financial Statements

None